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Introduction {#s1}
============

Mono(2-ethylhexyl) phthalate (MEHP) is the primary metabolite of the common plasticizing agent di(2-ethylhexyl) phthalate (DEHP). DEHP is widely used in polyvinyl chloride (PVC) materials, which can easily accumulate in the body via exposure to medical devices, food, and indoor air ([@c10]). Some phthalates have been shown to cross the placental barrier and have been detected in placental tissues, amniotic fluid, and cord blood ([@c47]). Indeed, an analysis of umbilical cord blood samples obtained from 84 consecutive newborns born in a single hospital in Italy detected a mean MEHP concentration of $0.52 \pm 0.61\;\mu g/{mL}$ \[$1.86\;\mu M$\] ([@c35]). However, this concentration was dramatically higher in 21 maternal and 30 umbilical cord blood samples collected randomly from low birth weight (LBW) infants born in a third-grade Maternal and Child Health Hospital in Shanghai, China, ($11.87\;\mu g/\text{ml}$ \[$42\;\mu M$\] and $9.94\;\mu g/\text{ml}$ \[$35\;\mu M$\], respectively; [@c37]). Furthermore, although published results have been inconsistent ([@c67]), several studies have reported that maternal exposure to phthalates during pregnancy is linked to changes in placental size and shape ([@c76]), fetal growth parameters ([@c28]; [@c59]), preterm birth ([@c17]), pregnancy loss ([@c23]), and altered neurodevelopment in infants ([@c16]) and children ([@c61]). In addition, phthalates are classified as endocrine-disrupting compounds as they adversely affect the endocrine system ([@c41]).

Healthy fetal development is highly dependent on proper placental growth throughout pregnancy ([@c5]). During the process of placenta formation, mononucleated villous cytotrophoblasts (VCTs) either: *a*) proliferate and differentiate into highly invasive extravillous cytotrophoblasts (EVCTs), which can invade the maternal endometrium and remodel the spiral arteries, or *b*) fuse and form the continuous, multinucleated syncytiotrophoblast (ST). The ST, which forms the outermost surface of the placental chorionic villi, is located at the interface between maternal and fetal circulation. This multinucleated layer regulates gas and nutrient exchange, supports intensive endocrine functions, and provides immunological support to the fetus. A better understanding of the processes of differentiation and fusion of VCTs to form the ST is essential because disturbance of this regulation is thought to be associated with pregnancy disorders such as preeclampsia (PE) and intrauterine growth retardation (IUGR) ([@c30]; [@c39]; [@c54]). Fortunately, this fusion process can be studied *in vitro*, using primary cultures of VCT. The functionality of the ST is then assessed through the measurement of hCG released in the supernatant ([@c11]; [@c60]).

Peroxisome proliferator--activated $\text{receptor}\,\gamma$ ($\text{PPAR}\gamma$) is a member of the nuclear receptor superfamily that binds the peroxisome proliferator response element (PPRE) sequence to regulate, in a ligand-dependent manner, the transcription of target genes. $\text{PPAR}\gamma$ is involved in embryonic development ([@c7]; [@c48]), lipid metabolism ([@c36]; [@c56]), insulin resistance ([@c24]), inflammation ([@c24]), immune response, and differentiation of several tissues, including the placenta and trophoblast ([@c7]; [@c60]). In the human placenta, $\text{PPAR}\gamma$ is expressed in *a*) EVCTs, as an essential regulator of EVCT invasion ([@c20]) and *b*) VCTs, where its activation has been demonstrated during syncytialization ([@c55]; [@c60]). Furthermore, altered expression or activation of $\text{PPAR}\gamma$ has been observed in placental pathologies such as IUGR and PE (higher $\text{PPAR}\gamma$ expression ([@c27]) and lower $\text{PPAR}\gamma$ activity ([@c45]; [@c69]), respectively).

Recent *in vitro* studies have reported that MEHP inhibits human EVCT invasion ([@c22]) and hCG secretion by the villous trophoblast ([@c3]). These effects could potentially be mediated by MEHP acting as an exogenous ligand for $\text{PPAR}\gamma$. For this reason, the possible role of $\text{PPAR}\gamma$ in the effects of MEHP on placental development and, more precisely, on VCT differentiation is of particular interest. The present study was designed to *a*) investigate the action of MEHP on *in vitro* differentiation of VCT and hCG secretion, *b*) characterize the effect of MEHP on $\text{PPAR}\gamma$ expression and activity, and *c*) analyze the lipid profiles of MEHP-treated cells.

Materials and Methods {#s2}
=====================

Reagents {#s2.1}
--------

MEHP (\#ALR-138N) was purchased from AccuStandard Inc., $\text{PPAR}\gamma$ agonist (GW1929, \#ab142213) and antagonist (GW9662, \#ab141125) from Abcam, and dimethyl sulfoxide (DMSO, \#D2650) from Sigma-Aldrich.

Ethical Statement {#s2.2}
-----------------

The study was performed according to the principles of the Declaration of Helsinki. Placentas were obtained with the patients' written informed consent. The protocol was approved by the local ethics committee (CPP 2015-mai-13,909). Placental tissues were obtained from women who underwent normal cesarean section at the Cochin Port-Royal, Antony, and Montsouris maternity units (Paris, France). The reasons for cesarean section were as follows: breech delivery or transverse presentation, multiple scars on the uterus, and narrow pelvis. The women had otherwise uncomplicated pregnancies as determined from their medical health records. Because placentas are given anonymously, no details about the demographics of the population (age, race/ethnicity) or reason for the normal cesarean section could be obtained.

Distribution of Placental Materials {#s2.3}
-----------------------------------

In this study, a total of $n = 23$ placentas (10 males and 13 females) were examined, with the number of placentas varying among experiments. For investigations of VCT viability/cytotoxicity/apoptosis, $n = 5$ placentas were used; for cell $\text{fusion}/\text{PPAR}\gamma$ activity assays and western blots, $n = 3$ placentas. For lipidomics analyses, which required a high number of treated cells and a high number of placentas to be significant, three treatments (vehicle, 0.1, and $10\;\mu M$ MEHP) were performed on $n = 12$ placentas (5 males and 7 females). For hCG quantification in treated cells (vehicle, $\text{PPAR}\gamma$ agonist/antagonist, 0.1, 1 and $10\;\mu M$ MEHP) $n = 11$ placentas (5 males and 6 females) were used; these corresponded to those used in the cell $\text{fusion}/\text{PPAR}\gamma$ activity assays ($n = 3$), western blots ($n = 3$), and some of those used in lipidomics analyses ($n = 5$) to ensure the donor-independency of the results.

Cell Culture and Treatment {#s2.4}
--------------------------

VCTs were isolated from human term placentas ($n = 23$, 10 males and 13 females) as previously described ([@c4]; [@c13]; [@c21]). Briefly, several cubic millimeters of the basal plate surface were removed with a sharp blade. Villous tissue was gently scraped free from blood vessels and connective tissue using forceps. After washing thoroughly two times with DMEM and once in 1X ${Ca}^{2 +}\text{-}$ and ${Mg}^{2 +}\text{-free}$ HBSS, the tissue was cut into small pieces. About $15\; g$ of minced tissues were digested once in $50\,\text{ml}$ of a filtered digestion enzyme medium, which contained $500\;{mg}$ of trypsin powder (\#27250-018, Sigma-Aldrich), $17.5\,\text{ml}$ fat-free milk, $250\;\mu l$ DNase I ($50\; U/\text{ml}$), $250\;\mu l$ $0.1\; M$ $\text{MgSO}_{4}$ (\#5886-0500, Merck) and $250\;\mu l$ $0.1\; M$ $\text{CaCl}_{2}$ (\#1-02820-1000, Merck) in $250\,\text{ml}$ warm 1X ${Ca}^{2 +}\text{-}$ and ${Mg}^{2 +}\text{-free}$ HBSS. The mixture was placed in a shaking incubator ($50\,\text{rpm}$) at 37°C for 30 min. Then the tissues were incubated with $30\,\text{ml}$ of the digestion medium for 10 min; this step was performed up to five times. Enzymatic degradation was monitored under light microscopy and was stopped by filtering the mixture through a $40\text{-}\mu m$ strainer into $50\text{-ml}$ tubes containing 5% FBS. Cell suspensions were collected and centrifuged at $1200\,\text{rpm}$ for 10 min at room temperature. Cell pellets were suspended in $3\,\text{ml}$ of DMEM, laid on top of a preformed Percoll gradient (60%, 50%, 45%, 35%, 30%, 20%, and 10%) and centrifuged at $2500\,\text{rpm}$ at room temperature without braking for 20 min. The layer between 45% and 35% Percoll contained the trophoblast cells; this was collected, suspended in DMEM, and centrifuged at $1200\,\text{rpm}$ at room temperature for 10 min. The resulting cell pellet was suspended in DMEM supplemented with 10% FCS, $2\,\text{mM}$ glutamine, $100\,\text{IU}/{mL}$ penicillin, and $100\;\mu g/{mL}$ streptomycin (Gibco 15140-122), and the cells were counted using a TC20™ Automated Cell Counter (Biorad). The cells were cultured in 5% ${CO}_{2}$ at 37°C. After overnight incubation, cells were treated with MEHP, $\text{PPAR}\gamma$ agonist ($1\;\mu M$ GW1929), or $\text{PPAR}\gamma$ antagonist ($1\;\mu M$ GW9662). After 72 h of culture, cells were preserved in one of two ways: 1) fixed with 4% PFA for 20 min at room temperature, washed three times in PBS, then stored in PBS at 4°C until immunostaining was performed, or 2) snap-frozen: cells were washed two times with cold PBS, scraped into $1\,\text{ml}$ cold PBS and transferred into a $1.5\,\text{ml}$ tube. After centrifugation (a 10 s pulse at $14,000\,\text{rpm}$), the PBS supernatants were discarded and the cell pellets were snap-frozen in liquid nitrogen and stored at $- 80{^\circ}C$ until RT-qPCR, western blot, or lipidomics analyses were conducted. Cell supernatants were collected and stored at $- 20{^\circ}C$ until determination of hCG concentration was carried out. For explants cultures, chorionic villi from term placentas ($n = 3$) were cultured in triplicate, placed in a 24-well plate using a folded pin and cultured in $2\,\text{ml}$ of DMEM supplemented with 10% FCS, $2\,\text{mM}$ glutamine, $100\,\text{IU}/{mL}$ penicillin, and $100\;\mu g/{mL}$ streptomycin with or without MEHP ($0.1\;\mu M$, $1\;\mu M$ or $10\;\mu M$). After 48 h of culture, explants were fixed with 4% PFA overnight at 4°C, then washed 3 times and stored in 1X PBS at 4°C until use.

Cell Viability, Cytotoxicity, and Apoptosis Assays {#s2.5}
--------------------------------------------------

The effect of MEHP on cell viability, cytotoxicity, and apoptosis was measured using the ApoTox-Glo™ Triplex Assay (\#G6321) from Promega, following the manufacturer's instructions. We plated 40,000 cells/well of a 96-well plate (\#3904, Corning). After 16 h of culture, cells were exposed to 0.1, 1, 10, 50, 100, and $500\;\mu M$ MEHP for 24 h and 48 h. This assay detects a fluorogenic, cell-permanent peptide substrate (GF-AFC) for the determination of live-cell protease activity, and a cell-impermanent, fluorogenic peptide substrate (bis-AAF-R110) for the quantification of dead-cell protease activity; in this way, it is possible to quantify cell viability and cytotoxicity using two proportional, inversely correlated measures. The live- and dead-cell proteases produce different products, AFC and R110, respectively, which have different excitation and emission spectra, allowing them to be detected simultaneously.

A third aspect of the assay quantifies luciferase fluorescence to measure apoptosis. For this, we added luminogenic DEVD-peptide substrate for caspase-3/7 and Ultra-Glo recombinant Thermostable Luciferase to cells, which were provided in the kit. The presence of Caspase-Glo® 3/7 Reagent resulted in cell lysis, followed by caspase cleavage of the substrate and generation of a "glow-type" luminescent signal produced by luciferase. Fluorescence at $400\text{Ex}/505\text{Em}$ (viability) and $485\text{Ex}/520\text{Em}$ (cytotoxicity) and luminescence were measured using an EnSpire Multimode Plate Reader (Perkin Elmer). The percentage of cells was determined by comparing the luminescent signal of MEHP-treated cells to vehicle (DMSO treatment).

Transfection {#s2.6}
------------

After 16 h of culture, cells were treated for 2 h with 0.1, 1, or $10\;\mu M$ MEHP, $1\;\mu M$ GW1929, or $1\;\mu M$ GW9662, which were diluted in a culture medium containing 1X glutamine and 10% FCS (without PS). Before transfections, cells were washed and then incubated with Opti-MEM I medium without serum (\#11058021, Gibco; $200\;\mu l/12\text{-well}$ removable chamber, \#81201, Ibidi, or $500\;\mu l/24\text{-well}$ plate, \#3524, Corning). $\text{PPAR}\gamma$ activity assays were performed as previously described ([@c14]). Briefly, for transient transfection with PPRE-H2B-eGFP, VCTs were plated in 12-well cell-culture--treated plastic slides (40,000 cells/well). For transient transfection with PPRE-pNL1.3 or pNL1.3 basic secreted luciferase reporter as control, VCTs were plated in 24-well plates (250,000 cells/well). In both conditions, cells were transfected using Lipofectamine® 3000 (Invitrogen) following the manufacturer's protocol. Four hours later, the transfected cells were washed and treated again with 0.1, 1, or $10\;\mu M$ MEHP, $1\;\mu M$ GW1929, or $1\;\mu M$ GW9662 for 48 h.

Immunofluorescence and Image Analysis {#s2.7}
-------------------------------------

After 72 h of culture, cells were fixed in 4% PFA for 20 min at room temperature, washed in PBS, and permeabilized in 0.5% Triton X-100 in PBS for 30 min. Then, cells were blocked in 5% IgG-free BSA and placed in 0.1% Tween-20 in PBS for 1 h at room temperature. For the fusion index assay, cells were incubated overnight at 4°C with $2\mu g/\text{ml}$ of TWIST1 (\#ab50887, Abcam) or GATA3 (\#sc-268, Santa Cruz Biotechnology) and desmoplakin (\#ab71690, Abcam) primary antibodies in blocking solution, as described in [@c12]. The next day, cells were rinsed three times with 0.1% Tween-20 in PBS (PBST), then the staining was revealed with the VectaFluor™ Excel R.T.U. Antibody Kit using DyLight® 488 Anti-Mouse IgG antibody (\#DK-2488, Vector Laboratories) according to the manufacturer's instructions. After three washes with PBST, cells were incubated with Alexa Fluor® 555 Donkey anti-Rabbit IgG ($H + L$) Highly Cross-Adsorbed secondary antibody (\#A31572, Invitrogen; 1:500 in PBST) for 1 h in the dark at room temperature, then washed three times in PBST and counterstained with DAPI for 10 min at room temperature. For PPRE-H2B-eGFP experiments, cells were incubated with Alexa Fluor® 555 Phalloidin (\#A34055, Invitrogen; 1:200 in PBST) for 1 h, in the dark at room temperature, then washed three times in PBST, and counterstained with DAPI for 10 min at room temperature, as described in [@c14]. Finally, slides were mounted with Fluoromount-G (\#FP-483331, Interchim) and stored at 4°C. Confocal microscopy images (obtained with a Leica spinning-disk microscope equipped with a Plan Apo 63X/1.4 oil objective and a CoolSnap HQ2 CCD camera) were processed with ImageJ (National Institutes of Health; <https://imagej.nih.gov/ij/>) or Icy (Institut Pasteur; <http://icy.bioimageanalysis.org/>). The fusion index was calculated in three placentas from seven nonoverlapping images per replicate and determined as \[$\%\,\left( {\text{number}\,\text{of}\,\text{TWIST}1 + \text{nuclei}/\text{total}\,\text{number}\,\text{of}\,\text{DAPI}\,\text{nuclei}} \right)$\] or \[$100 - \%\,\left( {\text{number}\,\text{of}\,\text{GATA}3 + \text{nuclei}/\text{total}\,\text{number}\,\text{of}\,\text{DAPI}\,\text{nuclei}} \right)$\] as previously described ([@c12]). Quantification of PPRE-H2B-eGFP was performed on a minimum of 100 nuclei per condition in three independent experiments. For quantification, fluorescent signals were integrated over the entire nucleus as previously described ([@c14]).

Neutral Lipid Staining {#s2.8}
----------------------

Placental explants were blocked in 5% IgG-free BSA in PBS for 1 h at room temperature and then incubated overnight at 4°C with BODIPY 505/515 ($10\mu g/\text{ml}$, Molecular probes) and Cytokeratin 7 (CK7, a trophoblast-specific marker) primary antibody ($1\;\mu g/\text{ml}$, \# SAB4501652, Sigma). The next day, explants were rinsed three times with PBS, and incubated 1 h at room temperature with an Alexa Fluor® 555 Donkey anti-Rabbit IgG ($H + L$) Highly Cross-Adsorbed secondary antibody (\#A-31572, Invitrogen; 1:500 in PBS). After three washes with PBS, nuclei were counterstained with DAPI for 20 min at room temperature. Finally, slides were mounted with Fluoromount-G™ (\#FP-483331, FluoProbes) and stored at 4°C. Confocal microscopy images were obtained with a Leica SP8 inverted microscope equipped with a Plan Apo oil-immersion x40 objective (numerical aperture 1.30). BODIPY fluorescence intensity ($n = 3$, 5 nonoverlapping images per replicate) was quantified with ImageJ (National Institutes of Health; <https://imagej.nih.gov/ij/>).

hCG Assay {#s2.9}
---------

hCG concentrations ($n = 11$, 5 males and 6 females) were measured using the $\text{CG} + \beta$ assay on a cobas e801 analyzer (Roche). This immunoassay uses two different antibodies: a biotinylated monoclonal mouse antibody for capture and a monoclonal mouse antibody labeled with ruthenium for electrochemiluminescence detection (ECLIA). The parameters of the assay were as follows: range $1–10,000\,\text{UI}/L$, $\text{LOQ}\, < \,\, 0.6\,\text{UI}/L$, no cross-reaction with FSH, TSH; $\text{LH} = 0.12\%$, accuracy: within run $\text{CV} < \,\, 3\%$ and between run $< 8\%$.

RNA Isolation and Real-Time qPCR {#s2.10}
--------------------------------

Total RNA from cells was purified on RNeasy columns (Qiagen) according to the manufacturer's protocol and quantified using a Nanodrop spectrophotometer. Reverse transcriptions ($250\,\text{ng}$ total RNA) were performed using Superscript III (Invitrogen) with random hexamers. cDNA was prepared in duplicate and pooled to perform qPCR. As previously described ([@c57]), real-time quantitative RT-PCR was performed in triplicate with qPCR MasterMix Plus for SYBR Green (Eurogentec). using an ABI Prism 7900 Sequence Detection system (Applied Biosystems) under the following conditions: an initial denaturation step (95°C for 10 min); 40 cycles of 95°C for 15 s, then 60°C for 60 s; followed by a three-step dissociation phase of 15 s at 95°C, 30 s at 60°C, and 15 s at 95°C to eliminate possible artifacts such as oligonucleotide dimers. The primer sequences were as follows: $\text{PPAR}\gamma$ (Peroxisome proliferator--activated receptor gamma) forward primer: 5′- AGTGGGGATGTCTCATAATGCC-3′, reverse primer: 5′- AGGTCAGCGGACTCTGGATTC-3′; 18S forward primer: 5′- TCCCCCAACTTCTTAGAGG-3′, reverse primer: 5′- CTTATGACCCGCACTTACTG-3′; HPRT1 (Hypoxanthine Phosphoribosyltransferase1) forward primer: 5′-GGCGTCGTGATTAGTGATG-3′, reverse primer: 5′- CAGAGGGCTACAATGTGATG-3′; RPLP0 (Ribosomal protein lateral stalk subunit P0) forward primer: 5′- AACATCTCCCCCTTCTCCT-3′, reverse primer: 5′- ACTCGTTTGTACCCGTTGAT-3′; SDHA (Succinate dehydrogenase complex flavoprotein subunit A) forward primer: 5′- CCACCACTGCATCAAATTCATG-3′, reverse primer: 5′- TGGGAACAAGAGGGCATCTG-3′. The relative RNA expression of each gene was normalized with the geometric mean of four endogenous controls (18S, HPRT, RPLP0, and SDHA) using qBasePlus 2 Software (Biogazelle).

Western Blotting {#s2.11}
----------------

Total cell extracts were prepared from snap-frozen cell pellets using RIPA buffer \[$5\,\text{mM}$ Tris-HCl (pH 7.6), $150\,\text{mM}$ NaCl, 1% NP-40, 1% bodium desoxycholate, 0.1% SDS, containing freshly added protease inhibitors (\#539131, Calbiochem), and phosphatase inhibitors (\#524629, Calbiochem)\], and then sonicated. For mitogen-activated protein kinase (MAPK) analyses, protein lysates were centrifuged at $14,000 \times g$ for 10 min at 4°C, and the supernatants were transferred to a new tube. Protein concentrations were determined using the Pierce™ Micro BCA™ Protein Assay Kit (\#23235, Thermo Scientific). Equal amounts of proteins ($50\;\mu g$ or $20\;\mu g$) were separated on 4--15% SDS-PAGE mini-PROTEAN® TGX™ precast protein gel under reducing conditions (DTT) and transferred onto a $0.2\text{-}\mu m$ nitrocellulose membrane using a Trans-blot® Turbo™ Transfer System (Bio-Rad). For PPARG experiments, after blocking with 5% nonfat milk in TBST at room temperature for 1 h, membranes were incubated with primary antibodies in blocking solution at 4°C overnight. For MAPK experiments, after blocking with 3% BSA/TBST at 4°C overnight, membranes were incubated with primary antibodies in 1% BSA/TBST at room temperature for 3 h. The membranes were then washed three times with TBST at room temperature for 5 min and incubated with secondary antibodies at room temperature for 1 h. Finally, membranes were washed three times with TBST at room temperature for 5 min and scanned with an Odyssey® Imaging System (Li-Cor). The primary antibodies were: anti-$\text{PPAR}\gamma$ \[$0.5\;\mu g/\text{ml}$ (1:400; sc-7,196, Santa Cruz Biotechnology)\], anti-phospho- extracellular signal-regulated kinase (ERK) (p-ERK, 1:1,000; \#4370, Cell Signaling), anti-total-ERK (t-ERK, 1:1,000; \#4695, Cell Signaling), anti-phospho-P38 (p-P38, 1:1,000; \#4511, Cell Signaling), anti-total-P38 (t-P38, 1:1,000; \#8690, Cell Signaling), anti-phospho- c-Jun $\text{NH}_{2}\text{-}\text{terminal}$ kinase (JNK) (p-JNK, 1:1,000; \#9255, Cell Signaling), anti-total-JNK (t-JNK, 1:1,000; \#9252, Cell Signaling), $\text{anti}\text{-}\beta\text{-actin}$ ($0.2\;\mu g/\text{ml}$ (1:20,000; \#A5441, Sigma-Aldrich), and anti-vinculin ($0.1\;\mu g/\text{ml}$ (1:10,000; \#V9131, Sigma-Aldrich). The secondary antibodies were: Alexa Fluor® 680-conjugated donkey anti-Mouse IgG ($H + L$) Highly Cross-Adsorbed (1:20,000; \#A10038, Invitrogen) and Alexa Fluor® 790-conjugated donkey anti-Rabbit IgG ($H + L$) Highly Cross-Adsorbed (1:20,000; \#A11374, Invitrogen). Signal intensity was quantified using ImageJ software (National Institutes of Health; <https://imagej.nih.gov/ij/index.html>). The arbitrary pixel densities of each protein were normalized to actin or vinculin.

Nanoluciferase Assay {#s2.12}
--------------------

VCTs transfected with PPRE-pNL1.3 or basic pNL1.3 were cultured in triplicate in a 24-well plate (see paragraph "Transfection"). After 24 h of treatment, $100\;\mu l$ of each cell supernatant were dispensed into the wells of a 96-well plate (\#3610, Corning) and frozen at $- 20{^\circ}C$. After 48 h of treatment, the frozen 96-well plate was heated to room temperature and $100\;\mu l$ of each cell supernatant were dispensed into the wells of the same 96-well plate. The amount of secreted NanoLuc® luciferase activity was determined using the Nano-Glo® Luciferase Assay (\#N1130, Promega) based on the manufacturer's instructions. Luminescence in each well was then measured using an EnSpire Multimode plate reader (Perkin Elmer). Each luminescence reading was normalized to the average of the corresponding not-transfected control cells.

Lipid Extraction and Liquid Chromatography Mass Spectrometry Analysis {#s2.13}
---------------------------------------------------------------------

Cell pellets from cells treated for 48 h with vehicle, $0.1\;\mu M$, or $10\;\mu M$ MEHP (stored at $- 80{^\circ}C$ after snap-freezing in liquid nitrogen; $n = 12$, 5 males and 7 females) were ground twice using a Precellys® 24-Dual grinder (Bertin Technologies) at $5,000\,\text{rpm}$ with $1\;{mL}$ water for 15 s. After homogenization, lipids were extracted twice with a mixture of *tert*-butyl methyl ether/methanol/water (10:3:2.5, v/v/v), which contained 0.01% (w/v) of 3,5 Di-tert-4-butylhydroxytoluene. After centrifugation at $3,000\,\text{rpm}$ for 10 min, the supernatants were collected and evaporated under reduced pressure at 45°C. For the UPLC-MS analyses, lipid extracts were resuspended in an acetonitrile/isopropanol/chloroform/water mixture (35:35:20:10, v/v/v/v). Liquid chromatography-electrospray ionization mass spectrometry analysis of lipid extracts was performed on a Synapt® G2 High Definition MS™ (Q-TOF) mass spectrometer (Waters) combined with a UPLC system (Waters). Chromatographic separation was performed on an Acquity CSH C18 column ($100 \times 2.1\;{mm}$; $1.7\;\mu m$) set at 50°C; the binary gradient system used $10\,\text{mM}$ ammonium acetate in an acetonitrile/water mixture as solvent A (40:60, v/v) and $10\,\text{mM}$ ammonium acetate in an acetonitrile/isopropanol mixture as solvent B (10:90, v/v). The following gradient was applied: The run began with 40% of solvent B, ramped to 100% over 10 min, and was held for 2 min before a rapid return to initial conditions, followed by 2.5 min of equilibration. The flow rate was kept at $0.4\;{mL}/\text{min}$ for 15 min. Data were collected both in positive ($\text{ESI} +$) and negative ($\text{ESI} -$) ionization modes at $50–1200\, m/z$ in the full scan mode. The source parameters were as follows: capillary voltage $3,000\; V$ ($\text{ESI} +$) and $2,400\; V$ ($\text{ESI} -$), cone voltage $30\; V$ ($\text{ESI} +$) and $45\; V$ ($\text{ESI} -$), source temperature 120°C, desolvation temperature 550°C, cone gas flow $20\; L/h$, and desolvation gas flow $1,000\; L/h$. Leucine enkephalin was used as the external reference compound (Lock-Spray™) for mass correction at a concentration of $0.2\,\text{ng}/{mL}$. Data were acquired in the resolution mode (20,000 FWHM at *m/z* 500) with a scan time of 0.1 s. Data acquisition was performed using Waters MassLynx™ software (version 4.1; Waters MS Technologies). XCMS was used for peak selection, deconvolution, alignment, and retention time correction, and to generate peak tables of *m/z* and retention time pairs with associated relative intensities for all detected peaks. Data were median centered, log~10~ transformed, and Pareto scaled before multivariate analyses.

Statistical Analyses {#s2.14}
--------------------

For cell viability, cytotoxicity, and apoptosis assays; nanoluciferase assays; western blots; quantification of fusion index; hCG secretion; and immunofluorescence imaging (PPRE-H2B-eGFP), all measurements were performed with at least three independent placentas. The data are expressed as the $\text{mean} \pm \text{SEM}$ of the indicated number for cell viability, cytotoxicity, apoptosis, and nanoluciferase assays, or $\text{mean} + \text{SD}$ of the indicated number for western blots and experiments on the fusion index, hCG secretion, and PPRE-H2B-eGFP. Statistical analysis (paired *t*-test) of each treated group vs. vehicle control was performed using GraphPad Prism 6.07 software. Results were considered significant if the *p*-value was $< 0.05$ (\*), $< 0.01$ (\*\*), $< 0.001$ (\*\*\*) or $< 0.0001$ (\*\*\*\*). For lipidomics experiments, multivariate statistical analyses were performed with $\text{SIMCA}\text{-}P +$ software 13.0.3 (Umetrics). Models were constructed using an unsupervised principal component analysis (PCA), a supervised partial least squares-discriminant analysis (PLS-DA), or orthogonal projections to latent structures-discriminant analysis (OPLS-DA). Variables were selected as potential markers according to their \|p(corr)\| ($\geq 0.5$) and Variable Importance in the Projection (VIP) score ($> 1$) from the OPLS-DA analysis. Lipids were annotated by comparing the experimental data against lipid metabolite databases, including metlin ([metlin.scripps.edu](http://metlin.scripps.edu)) and lipidmap ([www.lipidmaps.org](http://www.lipidmaps.org)) with a tolerance of $5\,\text{ppm}$. Accuracy on retention time (tR) values was used to confirm annotation, with a threshold at 15%. A univariate data analysis (Wilcoxon) with a false discovery rate \[(FDR)-adjusted $p < 0.01$\] controlling the false-positive rate associated with multiple comparisons, was performed to assess the whole lipids identified and the statistical significance of the difference in concentration in MEHP-treated (0.1 or $10\;\mu m$) lipid extracts between compared control (vehicle) samples.

Results {#s3}
=======

Effect of MEHP on Cell Viability, Cytotoxicity, and Apoptosis in Human Primary Cytotrophoblasts {#s3.1}
-----------------------------------------------------------------------------------------------

To evaluate the effect of MEHP on cell viability, cytotoxicity, and apoptosis, human primary cytotrophoblasts were exposed to MEHP at a serial dilution of 0.1 to $500\;\mu m$ for 24 h or 48 h. In comparison with treatment with vehicle (DMSO), treatment with $50\;\mu m$ or higher concentrations of MEHP resulted in significantly lower cell viability at 24 h and 48 h ([Figure 1](#f1){ref-type="fig"}, left panel). Only treatment with $500\;\mu m$ MEHP had a significant effect on cytotoxicity at 24 h and 48 h, as assessed by an extracellular protease activity assay for membrane integrity ([Figure 1](#f1){ref-type="fig"}, middle panel). Furthermore, treatment with $50\;\mu m$ or higher concentrations of MEHP resulted in significantly greater apoptosis \[caspase 3/7 activity, [Figure 1](#f1){ref-type="fig"}, right panel, or cleaved cytokeratin 18 (cCK18) immunostaining, Figure S1A\] at 24 h and 48 h than did treatment with vehicle. We observed no differences in cell viability, cytotoxicity, or apoptosis with media alone in comparison with vehicle control at 24 h and 48 h (Figure S1B). Accordingly, we conducted the remainder of the experiments with nontoxic concentrations of MEHP: 0.1, 1, and $10\;\mu M$. These concentrations are also consistent with those used on mouse 3T3-L1 ([@c42]) and on chicken germ cells ([@c25]).

![Effect of MEHP on VCT viability, cytotoxicity, and apoptosis as determined by ApoTox-Glo Triplex Assay (Promega). Cells were treated with various concentrations of MEHP (0.1, 1, 10, 50, 100, or $500\;\mu M$) for 24 h (circle, dashed line) or 48 h (triangle, solid line). The percentages were determined by comparing the fluorescent or luminescent signal of MEHP-treated cells to that of the vehicle (DMSO treatment). Values are presented as $\text{mean} \pm \text{SEM}$. ($n = 5$, in triplicate). Note: DMSO, dimethylsulfoxide; MEHP, mono(2-ethylhexyl) phthalate; ST, syncytiotrophoblast; VCT, villous cytotrophoblast. Statistical analysis was performed using paired *t*-test in comparison with vehicle control; \*^,^ †$p < 0.05$, \*\*^,^ ††$p < 0.01$, \*\*\*^,^ †††$p < 0.001$, \*\*\*\*^,^ ††††$p < 0.0001$. The asterisk (\*) indicates statistical significance of 24 h-treated cells, and the dagger (†) indicates statistical significance of 48 h-treated cells.](ehp3730_f1){#f1}

Effect of MEHP on Human VCT Differentiation {#s3.2}
-------------------------------------------

To investigate the effect of MEHP on the *in vitro* differentiation of human cytotrophoblast into STs, index fusion was calculated based on TWIST1 ([Figure 2A,B](#f2){ref-type="fig"}) or GATA3 (Figure S2A,B) immunostaining. In comparison with vehicle control, treatment with $10\;\mu M$ MEHP showed a significantly higher level of syncytialization (70% vs. 55%; $p < 0.0001$), similar to that obtained after treatment with the $\text{PPAR}\gamma$ agonist ($1\;\mu M$ GW1929; 75%). Instead, treatments with 0.1 or $1\;\mu M$ MEHP showed a significantly lower level of syncytialization (33%, 32%, respectively vs. 55%; $p < 0.0001$), similar to treatment with the $\text{PPAR}\gamma$ antagonist ($1\;\mu M$ GW9662; 32%).

![Effect of MEHP on trophoblast cell fusion and hCG secretion. After 16 h of culture, VCTs were treated for 48 h with either MEHP (0.1, 1, or $10\;\mu M$) or $1\;\mu M$ of $\text{PPAR}\gamma$ agonist (GW1929) or antagonist (GW9662). After 72 h of culture, (*A*) representative images are shown of cells fixed and subjected to fusion assay \[VCT and ST nuclei were immunostained with anti-TWIST1 (marker of ST, yellow) and anti-DESMOPLAKIN (red) antibodies and counterstained with DAPI (blue)\]. Scale bar: $20\;\mu m$. (*B*) Nuclei were counted manually using the "cell counter" plugin of ImageJ. Fusion index (%) was calculated as the % ($\text{number}\,\text{of}\,\text{TWIST}1 + \text{nuclei}/\text{total}\,\text{number}\,\text{of}\,\text{nuclei}$). Values are represented as $\text{mean} + \text{SD}$ of the percentage ($n = 3$ placentas, 7 non-overlapping images per replicate). (*C*) After 72 h of culture, hCG secretion was quantified in the media ($n = 11$). Values are presented as $\text{mean} + \text{SD}$ of value normalized to vehicle control. Note: MEHP, mono(2-ethylhexyl) phthalate; $\text{PPAR}\gamma$, peroxisome proliferator-activated receptor gamma; ST, syncytiotrophoblast; VCT, villous cytotrophoblast. Statistical analysis was performed using paired *t*-test in comparison with vehicle control; \*\*\*$p < 0.001$, \*\*\*\*$p < 0.0001$.](ehp3730_f2){#f2}

Effect of MEHP on hCG Secretion {#s3.3}
-------------------------------

Levels of hCG released by cytotrophoblasts in culture media were analyzed in the same cultures depicted in [Figure 2A,B](#f2){ref-type="fig"} and Figure S2A,B. It is interesting to note that cytotrophoblasts exposed to MEHP, regardless of MEHP concentration ([Figure 2C](#f2){ref-type="fig"}) or the sex of the cells (Figure S2C), released significantly less $\text{hCG}\beta$ (30--40% of control; $p < 0.0001$). These results support the idea that MEHP exposure inhibits hormonal functions in the cytotrophoblast.

Effect of MEHP on $PPAR\gamma$ Expression and Transcriptional Activity during Human VCT Differentiation {#s3.4}
-------------------------------------------------------------------------------------------------------

To investigate the involvement of $\text{PPAR}\gamma$ in the responses elicited by MEHP, we first looked at the mRNA and protein expression of $\text{PPAR}\gamma$. qPCR analysis revealed that in comparison with vehicle control, treatment with $10\;\mu M$ MEHP resulted in significantly higher $\text{PPAR}\gamma$ mRNA expression ($p < 0.001$), whereas treatments with $0.1\;\mu M$ yielded significantly lower $\text{PPAR}\gamma$ mRNA expression ($p < 0.01$). However, western blot analysis showed that MEHP exposure did not alter the levels of $\text{PPAR}\gamma$ proteins (Figure S3). We thus assessed the effect of MEHP on $\text{PPAR}\gamma$ transcriptional activity using two new reporter assays that we developed ([@c14]). The transfection of cytotrophoblasts with PPRE-H2B-eGFP plasmid created $\text{eGFP} + \text{nuclei}$ that reflected the intensity of $\text{PPAR}\gamma$ transcriptional activity ([Figure 3A,B,D](#f3){ref-type="fig"}). In comparison with vehicle control, treatment with $10\;\mu M$ MEHP resulted in significantly higher $\text{PPAR}\gamma$ activity (272 vs. 195; $p < 0.0001$), whereas treatments with 0.1 or $1\;\mu M$ yielded significantly lower $\text{PPAR}\gamma$ activity (58 and 27, respectively, vs. 195; $p < 0.0001$). The transfection of cytotrophoblasts with the PPRE-pNL1.3\[secNluc\] plasmid confirmed this: There was significantly higher $\text{PPAR}\gamma$ activity with $10\;\mu M$ MEHP (190 vs. 156; $p < 0.001$) and significantly lower $\text{PPAR}\gamma$ activity with 0.1 and $1\;\mu M$ MEHP (126 and 100, respectively vs. 156; $p < 0.001$) after 48 h of treatment ([Figure 3C--3E](#f3){ref-type="fig"}).

![Effect of MEHP on $\text{PPAR}\gamma$ activity. After 16 h of culture, VCTs were pretreated for 2 h with MEHP (0.1, 1, or $10\;\mu M$) or $1\;\mu M$ of $\text{PPAR}\gamma$ agonist (GW1929) or antagonist (GW9662). They were transfected for 4 h with PPRE-H2B-eGFP (green) or PPRE-pNL1.3\[secNluc\], then again received their original treatment for the next 48 h. $\text{PPAR}\gamma$ activity was first assayed by immunofluorescence: (*A*) cells were fixed, stained with phalloidin (red), and counterstained with DAPI (blue); then (*B*) PPRE-H2B-eGFP fluorescence intensity was quantified. Scale bar: $20\;\mu m$. We also determined $\text{PPAR}\gamma$ activity using the (*C*) Nano-Glo® Luciferase system (Promega). For each condition (triplicate), $100\;\mu l$ of culture media after 24 h or 48 h of treatment were analyzed and compared with not-transfected cells. (*D--E*) Data from 2B (*D*) and 2C (*E*) represented as dose--response curves following 48 h of treatment with different concentrations of MEHP (0.1, 1, and $10\;\mu M$) and control (vehicle). Values are presented as $\text{mean} \pm \text{SD}$ of the fluorescence intensity (*B, D*) ($n = 3$, $> 100$ nuclei) or $\text{mean} \pm \text{SEM}$ of the fluorescence intensity normalized to the not-transfected control (*C, E*) ($n = 3$ in triplicate). Note: MEHP, mono(2-ethylhexyl) phthalate; $\text{PPAR}\gamma$, peroxisome proliferator-activated receptor gamma; ST, syncytiotrophoblast; VCT, villous cytotrophoblast. Statistical analysis was performed using paired *t*-test in comparison with vehicle control; \*\*\*$p < 0.001$, \*\*\*\*$p < 0.0001$.](ehp3730_f3){#f3}

Effect of MEHP on Lipid Profiles {#s3.5}
--------------------------------

To follow up on the observation that MEHP treatment significantly perturbed the activity of $\text{PPAR}\gamma$, a key regulator of lipid metabolism, we performed BODIPY staining on placental explants treated with vehicle, $0.1\;\mu M$, or $10\;\mu M$ MEHP. The appearance of the lipid vesicles is presented in [Figure 4A](#f4){ref-type="fig"}, with the lipid vesicles stained green in the ST and mesenchymal cells (MC). In comparison with vehicle control, treatment with $10\;\mu M$ MEHP resulted in significantly higher levels of lipid droplets ([Figure 4B](#f4){ref-type="fig"}). Instead, treatments with 0.1 or $1\;\mu M$ MEHP showed significantly lower levels of lipid droplets ([Figure 4B](#f4){ref-type="fig"}). To compare the global lipid profiles of cytotrophoblasts that were treated with vehicle, 0.1, and $10\;\mu M$ MEHP for 48 h, UPLC/QTOF MS data were used in PCA, PLS-DA, and OPLS-DA. OPLS-DA score plots showed a significant separation among the three groups ([Figure 5A--E](#f5){ref-type="fig"}), in both positive mode ([Figure 5A,C,D,E](#f5){ref-type="fig"}), and negative ion mode ([Figure 5B](#f5){ref-type="fig"}). As shown in Table S1, treatment with $0.1\;\mu M$ MEHP and $10\;\mu M$ MEHP affected the expression of 50 and 115 lipid species, respectively. Among these were glycerophospholipids, including lysophosphatidic acids (LPA), lysophosphatidycholines (LPC), lysophosphatidylethanolamines (LPE), lysophosphatidylglycerols (LPG), phosphatidic acids (PA), phosphatidylcholines (PC), phosphatidylethanolamines (PE), phosphatidylglycerols (PG), and phosphatidylserines (PS), as well as glycerolipids such as diglyceride (DG), monoacylglycerols (MG), and fatty acids (FA). Analysis and quantification of individual classes of lipids from the total lipid fraction are shown in [Figure 5F](#f5){ref-type="fig"}. In comparison with vehicle control, cells treated with $0.1\;\mu M$ or $10\;\mu M$ MEHP showed different lipid profiles. Overall, cells treated with $10\;\mu M$ MEHP showed significantly higher levels of all glycerolipids (FA, MG, DG), PC, PS, phosphatidylserine plasmalogens (PS-P), and phosphatidic acid plasmalogens (PA-P) than cells treated with $0.1\;\mu M$ MEHP or controls showed. The former group also showed significantly lower levels of phosphatidylcholine plasmalogens (PC-P) and phosphatidylethanolamine plasmalogens (PE-P) than the latter or controls showed. Instead, $0.1\;\mu M$ MEHP-treated cells showed significantly lower levels of PC, LPG, PS, PS-P and all phosphatidic acid subclasses (PA, PA-P, LPA) than $10\;\mu M$ MEHP-treated cells or controls showed. Regardless of the concentration ($0.1\;\mu M$ or $10\;\mu M$), MEHP-treated cells had significantly higher levels of LPE and PG.

![Effect of MEHP on lipid synthesis in human term placental explants. Placental explants were treated for 48 h with MEHP (0.1, 1, or $10\;\mu M$). (*A*) Representative images are shown of placental explants fixed and subjected to lipid droplet labeling. Placental explants were stained with BODIPY (505/515, green), immunostained with anti-cytokeratin 7 (CK7, red) antibody (a trophoblast-specific marker), and then counterstained with DAPI (blue). Scale bar: $20\;\mu m$. (*B*) Quantification of total fluorescence of BODIPY. Values are presented as $\text{mean} + \text{SD}$ of the fluorescence intensity ($n = 3$, 5 non-overlapping images per replicate). Note: MC, mesenchymal cells; MEHP, mono(2-ethylhexyl) phthalate; ST, syncytiotrophoblast. Statistical analysis was performed using paired t-test compared to vehicle control; \*\*$p < 0.01$, \*\*\*\*$p < 0.0001$.](ehp3730_f4){#f4}

![Effect of MEHP on lipid metabolic profiles. OPLS-DA score plots are shown of the cellular lipidome in cells that were treated with control (DMSO vehicle) or MEHP ($0.1\;\mu M$ or $10\;\mu M$) ($n = 12$ per group). Lipid profiles were obtained in (*A*) positive ionization mode and (*B*) negative ionization mode. (*C*) OPLS-DA score plots are shown of the cellular lipidome in positive ionization mode from cells treated with vehicle or $0.1\;\mu M$ MEHP, (*D*) vehicle or $10\;\mu M$ MEHP, or (*E*) $0.1\;\mu M$ or $10\;\mu M$ MEHP. (*F*) Intensities of lipid subclasses in vehicle- and MEHP-treated cells. The intensity of a subclass corresponds to the $\text{mean} + \text{SEM}$ of the intensities of each lipid in all samples belonging to the same class. A univariate data analysis (Wilcoxon) corrected for the false discovery rate ((FDR)-adjusted $p < 0.01$) was performed between MEHP-treated (0.1 or $10\;\mu M$) cells in comparison with vehicle control; \*$p < 0.05$, \*\*$p < 0.01$, \*\*\*^,^ †††$p < 0.001$. The asterisk (\*) indicates a statistically significant difference between MEHP-treated cells (0.1 or $10\;\mu M$) and vehicle-treated cells, and the dagger (†) indicates statistical a significant difference between of $0.1\;\mu M$ and $10\;\mu M$ MEHP-treated cells. Details of lipid species that were differentially expressed among these lipid sub-classes are listed in Table S1. Note: DG, diacylglycerols; DMSO, dimethylsulfoxide; FA, fatty acids; LPA, lyso-PA; LPC, lyso-PC; LPG, lyso-PG; LPE, lyso-PE; MEHP, mono(2-ethylhexyl) phthalate; MG, monoacylglycerols; PA, phosphatidic acids; PA-P, PA plasmalogens;PC, phosphatidylcholines; PC-P, PC plasmalogens; PE, phosphatidylethanolamines; PE-P, PE plasmalogens; PG, phosphatidylglycerols; PG-P, PG plasmalogens; PS, phosphatidylserines; PS-P, PS plasmalogens.](ehp3730_f5){#f5}

Effect of MEHP on MAPK Pathway {#s3.6}
------------------------------

We also examined the effects of MEHP on the MAPK pathway, which is essential for cytotrophoblast differentiation ([@c64]). After 72 h of culture, *in vitro* differentiated ST were treated with vehicle, 0.1, 1, or $10\;\mu M$ MEHP for 15 and 30 min; we then determined differences in activation of ERK, P38, and JNK by western blotting ([Figure 6A](#f6){ref-type="fig"}). In comparison with vehicle control, all MEHP-treated ST (except 15-min treatment with $1\;\mu M$ MEHP) had significantly higher ratios of p-ERK/t-ERK and p-P38/t-P38; notably, we observed a U-shaped dose-dependent pattern activation of ERK and P38 ([Figure 6B](#f6){ref-type="fig"}). In comparison with vehicle control, 15-min treatment with $1\;\mu M$ or $10\;\mu M$ MEHP resulted in a significantly lower ratio of p-JNK/t-JNK, whereas a 30-min treatment with $0.1\;\mu M$ or $10\;\mu M$ MEHP yielded a significantly higher ratio of p-JNK/t-JNK and a significantly lower ratio of p-JNK/t-JNK, respectively ([Figure 6B](#f6){ref-type="fig"}).

![Effect of MEHP on the MAPK pathway. After 72 h of culture, *in vitro* differentiated VCTs were treated for 15 or 30 min with MEHP (0.1, 1, or $10\;\mu M$). (*A*) Representative images of western blots. Proteins ($50\;\mu g$) were loaded in 4--12% Tris-Bis gradient gels, and then blots were probed with anti-p-ERK, t-ERK, p-P38, t-P38, p-JNK, t-JNK, and vinculin antibodies. (*B*) The protein level was calculated by densitometry using ImageJ. Values are presented as the $\text{mean} + \text{SD}$ of the densitometric value relative to vinculin and normalized to vehicle control ($n = 3$). Note: DMSO, dimethylsulfoxide; MAPK, mitogen-activated protein kinases; MEHP, mono(2-ethylhexyl) phthalate; ST, syncytiotrophoblast. Statistical analysis was performed using paired *t*-tests in comparison with vehicle control; \*$p < 0.05$, \*\*$p < 0.01$, \*\*\*$p < 0.001$, \*\*\*\*$p < 0.0001$.](ehp3730_f6){#f6}

Discussion {#s4}
==========

The majority of previous studies aimed at monitoring MEHP in pregnant women have focused on blood or urine samples ([@c1]; [@c35]; [@c37]). *In vitro* studies offer the opportunity to characterize the responses of specific cell types to a chemically defined pollutant in isolation from systemic influences. Using this approach, our study demonstrated, to our knowledge for the first time, that MEHP affects villous trophoblast differentiation. Importantly, the doses employed in this study reflected physiologically relevant concentrations that have been detected in pregnant women \[$0.7\;\mu M$ in maternal urine ([@c2]), $2.45\;\mu M$ and $1.86–2.45\;\mu M$ in maternal and cord blood, respectively ([@c35]), and $42\;\mu M$ and $35\;\mu M$ in maternal and cord blood, respectively, in cases of LBW infants ([@c37])\].

Previous studies on the effects of MEHP on $\text{PPAR}\gamma$ in the trophoblast have mostly used cell lines. For example, experiments in human HTR-8/SVneo cells showed that MEHP inhibits human extravillous trophoblast invasion via the $\text{PPAR}\gamma$ pathway ([@c22]), and analysis of rat HRP-1 cells showed that MEHP disturbs the mRNA expression of $\text{PPAR}\gamma$ ([@c73]). In these studies, a relatively high dose of MEHP was used ($100\;\mu M$ and $50\;\mu M$, respectively). A more recent study performed on primary VCTs showed that after 40 h of treatment with $0.7\;\mu M$ MEHP, hCG secretion decreased significantly in a sex-independent manner ([@c3]). The authors found no change in $\text{PPAR}\gamma$ protein expression, but no further investigation was done on $\text{PPAR}\gamma$ activity, lipid metabolism, and VCT differentiation. The results of our study were in concordance with these previous reports (no change in $\text{PPAR}\gamma$ protein expression, inhibition of $\text{hCG}\beta$); however, to our knowledge, ours is the first study to report a U-shaped or nonmonotonic dose--response curve (NMDRC) for MEHP exposure on $\text{PPAR}\gamma$ activity.

The syncytialization of cytotrophoblast cells is central to human placental exchanges and hormone production ([@c29]). As syncytialization occurs, differentiated VCTs develop hormonal functions, with the increased synthesis and secretion of pregnancy hormones such as hCG. However, increased syncytialization without concomitant increases in hCG level has been previously observed in a study on the impact of formaldehyde on trophoblast differentiation and hormonal functions ([@c51]). As we observed here, those authors found that formaldehyde-exposed trophoblasts displayed an increase in cell fusion in comparison with control and showed a significant decrease in total hCG secretion. However, this study did not explain the molecular mechanism for the adverse effects on hCG secretion, but we know that changes in ST mass, formation, regeneration, or functioning can lead to abnormal endocrine production and provoke abnormal fetal development and miscarriage. Furthermore, hCG also acts in a paracrine and autocrine manner to trigger villous trophoblast differentiation and turnover throughout pregnancy ([@c52]). Clearly, the increased syncytialization we observed did not translate into improvement of trophoblast function, because we also observed a loss of secretion of hCG, the most important hormone of pregnancy. The production and secretion of hCG is essential at the beginning of pregnancy to induce progesterone synthesis by the ovarian corpus luteum, which leads to myometrium relaxation. In addition, through the first trimester of pregnancy, hCG is implicated in fusion and invasion processes of cytotrophoblasts and angiogenesis ([@c19]). Our results suggest that MEHP exposure alters cytotrophoblast differentiation and will probably affect fecundity as well as time of pregnancy, even if a few studies have actually found higher levels of phthalates to be associated with shorter time to pregnancy or reduced risk of early pregnancy loss ([@c8]; [@c31]; [@c66]).

Both low-dose effects and NMDRCs have been observed for a wide variety of endocrine-disrupting chemicals (EDCs) such as Bisphenol A ([@c65]). EDCs accomplish this disruption by mimicking or blocking the action of endogenous hormones, resulting in the inappropriate activation or inactivation of downstream pathways. Docking simulations to predict the binding mode of MEHP to the ligand-binding domain of $\text{PPAR}\gamma$ have shown 30 possible conformations and multiple interaction sites ([@c32]). Furthermore, NMDRCs can occur because of differences in receptor affinity, and thus the response selectivity, at low vs. high doses ([@c65]). In fact, several EDCs that have been shown to have low-dose effects are known to act via multiple receptors and pathways ([@c6]). Thus, the effects seen at high doses can be due to the binding of multiple receptors, whereas the effects of low doses may occur via only a single receptor or receptor family ([@c65]). The mechanisms are likely to be complex, possibly with multiple targets and pathways affected in the same tissue or even different, tissue-specific responses from a single EDC ([@c68]). Additional experiments are required, such as co-treatment with a $\text{PPAR}\gamma$ antagonist and transcriptomic work to determine which receptors contribute to the MEHP responses observed in this study and whether $\text{PPAR}\gamma$ is the dominant receptor mediating MEHP\'s agonizing effects at a high dose.

To examine whether MEHP exposure affected lipid metabolism, we first examined lipid droplet accumulation using BODIPY labeling. We observed a concordance between the U-shaped pattern of $\text{PPAR}\gamma$ activation in MEHP-treated VCT and lipid droplet accumulation in MEHP-treated placental villi. It is interesting to note that these experiments showed that MEHP crossed the placental barrier and affected lipid contents in all cell types (ST, VCT, and MCs). Indeed, we observed greater accumulation of lipid droplets in mesenchymal cells after a $10\;\mu M$ treatment with MEHP. As mesenchymal-trophoblast cross-talk has been proposed to play a major role in trophoblast cell fusion regulation ([@c50]), and as it has been described that adipogenic differentiation of mesenchymal stem cells is increased by secreted factors from adipose tissue ([@c72]), we can hypothesize that MCs (which could give rise to adipose cells) may secrete lipogenic factors that enhance $\text{PPAR}\gamma$ activation in VCT and ST though a paracrine process. Next, we conducted a global lipidomics analysis. Using OPLS-DA, we identified 115 lipids with differential expression in $10\;\mu M$ MEHP-treated cells in comparison with control, and 50 lipids in $0.1\;\mu M$ MEHP-treated cells, with only 20 lipids in common between the two treatments (Table S1). Our lipid profiling supports the idea that MEHP modifies lipid composition in a dose-dependent manner. It is interesting to note that cells treated with $10\;\mu M$ MEHP showed significantly higher levels of two glycerophospholipids (PC, PS) than cells treated with the lower concentration did. Membranes of eukaryotic cells are composed principally of glycerophospholipids, mostly phosphatidylcholines (PC), which play a critical role in regulating the physical properties (called "fluidity") of the membrane. The concentrations of these lipids thus influence the function of membrane proteins and the movement of proteins within the membrane ([@c33]), essential processes involved in cell fusion. Furthermore, $10\;\mu M$ MEHP-treated cells showed significantly higher levels of numerous polyunsaturated fatty acids (FA; $n = 11/16$, Table S1) than $0.1\;\mu M$ MEHP-treated cells did. These fatty acids are the principal precursors for the production of eicosanoids, such as prostaglandins, which are the natural ligands of $\text{PPAR}\gamma$ ([@c49]). It is also important to note that $\text{PPAR}\gamma$ activation can increase both esterification as well as lipolysis ([@c26]; [@c74]), which could explain the higher level of FA, MG, and DG in cells treated with $10\;\mu M$ of MEHP. These results may suggest the existence of a positive feedback loop of MEHP on $\text{PPAR}\gamma$ activation and membrane fluidity that could explain the higher cell fusion observed in $10\;\mu M$ MEHP-treated cells. In contrast, $0.1\;\mu M$ MEHP-treated cells had significantly lower levels of all phosphatidic acid subclasses (PA, PA-P, LPA) than $10\;\mu M$ MEHP-treated cells did. Phosphatidic acids have been shown to promote membrane fusion through their ability to change membrane topology called "curving" ([@c75]). Therefore, the lack of PAs in $0.1\;\mu M$ MEHP-treated cells could explain the low level of cell fusion observed.

As $\text{PPAR}\gamma$ has several sites of phosphorylation, $\text{PPAR}\gamma$ activity can be modulated by MAPKs, in particular ERKs; [@c9]). Because MAPKs are involved in cytotrophoblast differentiation ([@c64]), and have been reported to be impaired in human trophoblast HTR-8/SVneo cells treated with an environmental EDC (Benzo(a)Pyrene; [@c38]), we further investigated the molecular mechanisms of MEHP by the MAPK pathways. The MAPKs comprise ERKs, P38, and JNK. We found that MEHP disturbed all of these pathways, but in a different manner. In the present study, we observed increased levels of p-ERK and p-P38, and a lower level of p-JNK in cells treated with $10\;\mu M$ MEHP. This contrast could be explained by the fact that MAPKs are activated through distinct molecular signaling pathways. Activation of ERKs and P38 predominantly occurs through mitogenic stimuli, whereas the activation of JNK is mainly achieved through growth factors, environmental stresses, and proinflammatory stimuli ([@c34]). To our knowledge, our findings are the first to elucidate the effects of MEHP on cytotrophoblast differentiation, specifically with respect to its influence on $\text{PPAR}\gamma$ and MAPK pathways. It is interesting to note that the transcriptional activity of $\text{PPAR}\gamma$ is affected by cross-talk with kinases and phosphatases. Phosphorylation by ERK and other kinases can affect its activity in either a ligand-dependent or ligand-independent manner. Indeed, the effects of phosphorylation depend on the cellular context, receptor subtype, and residue metabolized, which can manifest at several steps: ligand affinity ([@c53]; [@c58]), DNA binding ([@c53]; [@c58]), coactivator recruitment ([@c53]; [@c58]), and proteasomal degradation of $\text{PPAR}\gamma$ ([@c18]).

Our study has a limitation. Given the origin of the placentas (Paris, France), the small size of samples, and the lack of demographic and biographical information for patients, our results may not be widely generalizable to other populations. However, even though it would be inadvisable to take our results completely at face value, the findings revealed here are largely consistent with previous studies and provide intriguing new avenues for study. In particular, our evidence of a U-shaped dose--response curve for MEHP clearly merits further investigation.

Conclusion {#s5}
==========

To conclude, this work suggested, to our knowledge for the first time, that MEHP has a U-shaped dose--response effect on $\text{PPAR}\gamma$ transcriptional activity as well as an impact on MAPK pathways, which together promote disturbances in lipid metabolism and in human VCT differentiation ([Figure 7](#f7){ref-type="fig"}). Our results support a role for MEHP as an endocrine disruptor in human trophoblasts by inhibiting hCG secretion. To our knowledge, we are the first to report an impact of environmentally relevant concentrations of MEHP on human ST formation, which is essential for a fully functional placenta ([@c44]). However, it is necessary to remember that organs are exposed to several phthalates that can accumulate and have additive or opposite effects, as recently described by [@c3].

![A proposed schematic diagram for MEHP impacts on villous cytotrophoblast cells. Features in solid black line and bold text represent results obtained in the present study; dashed lines represent potential regulation based on the literature (circle): ^1^([@c40]), ^2^([@c15]), ^3^([@c46]), ^4^([@c63]), ^5^([@c71]), ^6^([@c64]), ^7^([@c9]), ^8^([@c62]), ^9^([@c70]), ^10^([@c43]). Note: cAMP: Cyclic adenosine monophosphate; hCG, human chorionic gonadotropin; MAPK, mitogen-activated protein kinases; MEHP, mono(2-ethylhexyl) phthalate; $\text{PPAR}\gamma$, peroxisome proliferator-activated receptor gamma; PPRE, peroxisome proliferator response element; PTGS2, prostaglandin-endoperoxide synthase 2; ROS, reactive oxygen species.](ehp3730_f7){#f7}
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